Arcus Biosciences Statistics
Share Statistics
Arcus Biosciences has 105.89M
shares outstanding. The number of shares has increased by 16.37%
in one year.
| Shares Outstanding | 105.89M |
| Shares Change (YoY) | 16.37% |
| Shares Change (QoQ) | 15.66% |
| Owned by Institutions (%) | 91.8% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,632 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 7.91M, so 7.47% of the outstanding
shares have been sold short.
| Short Interest | 7.91M |
| Short % of Shares Out | 7.47% |
| Short % of Float | 11.45% |
| Short Ratio (days to cover) | 6.37 |
Valuation Ratios
The PE ratio is -4.74 and the forward
PE ratio is -2.04.
Arcus Biosciences's PEG ratio is
0.19.
| PE Ratio | -4.74 |
| Forward PE | -2.04 |
| PS Ratio | 5.2 |
| Forward PS | 1 |
| PB Ratio | 2.77 |
| P/FCF Ratio | -7.62 |
| PEG Ratio | 0.19 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcus Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.5,
with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.34 |
| Interest Coverage | -82.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $411,483.25 |
| Profits Per Employee | $-451,355.66 |
| Employee Count | 627 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1M |
| Effective Tax Rate | 0.35% |
Stock Price Statistics
The stock price has increased by -51.03% in the
last 52 weeks. The beta is 0.87, so Arcus Biosciences's
price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | -51.03% |
| 50-Day Moving Average | 8.44 |
| 200-Day Moving Average | 13.56 |
| Relative Strength Index (RSI) | 51.52 |
| Average Volume (20 Days) | 1,307,934 |
Income Statement
In the last 12 months, Arcus Biosciences had revenue of 258M
and earned -283M
in profits. Earnings per share was -3.14.
| Revenue | 258M |
| Gross Profit | 248M |
| Operating Income | -330M |
| Net Income | -283M |
| EBITDA | -268M |
| EBIT | -279M |
| Earnings Per Share (EPS) | -3.14 |
Full Income StatementBalance Sheet
The company has 150M in cash and 60M in
debt, giving a net cash position of 90M.
| Cash & Cash Equivalents | 150M |
| Total Debt | 60M |
| Net Cash | 90M |
| Retained Earnings | -1.13B |
| Total Assets | 1.16B |
| Working Capital | 839M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -170M
and capital expenditures -6M, giving a free cash flow of -176M.
| Operating Cash Flow | -170M |
| Capital Expenditures | -6M |
| Free Cash Flow | -176M |
| FCF Per Share | -1.95 |
Full Cash Flow StatementMargins
Gross margin is 96.12%, with operating and profit margins of -127.91% and -109.69%.
| Gross Margin | 96.12% |
| Operating Margin | -127.91% |
| Pretax Margin | -109.69% |
| Profit Margin | -109.69% |
| EBITDA Margin | -103.88% |
| EBIT Margin | -127.91% |
| FCF Margin | -68.22% |
